Archives of Medical Research
Volume 40, Issue 6 , Pages 478-485 , August 2009

The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm Change

  • Eduardo L. Franco

      Affiliations

    • Department of Oncology, McGill University, Canada
    • Department of Epidemiology & Biostatistics, McGill University, Canada
    • Corresponding Author InformationAddress reprint requests to: Prof. Eduardo Franco, McGill University, Division of Cancer Epidemiology, 546 Pine Avenue West, Montreal, QC, H2W 1S6 Canada; Phone: +1-514-398-6032; FAX: +1-514-398-5002
    • ,
  • Salaheddin M. Mahmud

      Affiliations

    • Department of Oncology, McGill University, Canada
    • Department of Surgery, McGill University, Canada
    • Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada
    • ,
  • Joseph Tota

      Affiliations

    • Department of Oncology, McGill University, Canada
    • Department of Epidemiology & Biostatistics, McGill University, Canada
    • ,
  • Alex Ferenczy

      Affiliations

    • Department of Pathology, McGill University, Canada
    • Department of Obstetrics & Gynecology, McGill University, Canada
    • Jewish General Hospital, Centre Hospitalier de l'Université de Montréal, Canada
    • ,
  • François Coutlée

      Affiliations

    • Department of Oncology, McGill University, Canada
    • Département de Microbiologie et Infectiologie, Centre Hospitalier de l'Université de Montréal, Canada

Received 12 May 2009 ,Accepted 15 May 2009.

References 

  1. IARC Working Group. Human papillomaviruses. IARC Monographs on the evaluation of carcinogenic risks to humans. Vol. 64. Lyon: International Agency for Research on Cancer; 1995;
  2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19
  3. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst. 1999;91:506–511
  4. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet. 2006;367:1247–1255
  5. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459–1466
  6. Ault KA Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861–1868
  7. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–2170
  8. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781–789
  9. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–615
  10. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915–1923
  11. Rogoza RM, Ferko N, Bentley J, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine. 2008;26:F46–F58
  12. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298:743–753
  13. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–285
  14. Benard VB, Eheman CR, Lawson HW, et al. Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995–2001. Obstet Gynecol. 2004;103:564–571
  15. Sangwa-Lugoma G, Mahmud S, Nasr SH, et al. Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer. 2006;119:1389–1395
  16. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342–362
  17. Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1157–1164
  18. Franco EL, Cuzick J, Hildesheim A, et al. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24:S171–S177
  19. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine. 2008;26S:A16–A23
  20. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810–819
  21. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–1105
  22. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579–1588
  23. Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111:167–177
  24. Miller AB, Nazeer S, Fonn S, et al. Report on consensus conference on cervical cancer screening and management. Int J Cancer. 2000;86:440–447
  25. Franco EL, Tsu V, Herrero R, et al. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine. 2008;26:L88–L95
  26. Spitzer M. Screening and management of women and girls with human papillomavirus infection. Gynecol Oncol. 2007;107:S14–S18
  27. Wright TC, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346–355
  28. Arbyn M, Buntinx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004;96:280–293
  29. Sankaranarayanan R, Nene BM, Dinshaw KA, et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer. 2005;116:617–623
  30. Kotaniemi-Talonen L, Nieminen P, Anttila A, et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer. 2005;93:862–867
  31. Kitchener HC, Almonte M, Wheeler P, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer. 2006;95:56–61
  32. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589–1597
  33. Bulkmans N, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764–1772
  34. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100:492–501
  35. Franco EL. Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr. 2003;31:89–96
  36. IARC Working Group. Cervix cancer screening. IARC Handbooks of Cancer Prevention, International Agency for Research on Cancer, World Health Organization. IARC Press; 2005;
  37. Arbyn M, Sasieni P, Meijer CJ, et al. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24:S78–S89
  38. Wright TC, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304–309
  39. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening:joint European cohort study. BMJ. 2008;337::a1754. doi:10.1136/bmj.a1754
  40. Depuydt CE, Arbyn M, Benoy IH, et al. Quality control for normal liquid based cytology: rescreening, high risk HPV targeted reviewing and/or high risk HPV detection?. J Cell Mol Med. 2008 Jun 9;[Epub ahead of print]
  41. Sasieni P, Cuzick J. Could HPV testing become the sole primary cervical screening test?. J Med Screen. 2002;9:49–51
  42. Cuzick J, Mayrand MH, Ronco G, et al. Chapter 10: New dimensions in cervical cancer screening. Vaccine. 2006;24:S90–S97

PII: S0188-4409(09)00094-0

doi: 10.1016/j.arcmed.2009.06.003

Archives of Medical Research
Volume 40, Issue 6 , Pages 478-485 , August 2009

Article Tools

* Image Usage & Resolution